BACKGROUND TO THE RESEARCH PROJECT

Despite optimal management of localised osteosarcoma disease, over 50% of patients develop metastatic disease or recurrence, which lead to poor survival outcomes in approximately 19 months.  Immunotherapies, activating immune cells to attack cancers, became standard therapy in many other cancer types and enabled prolonged effects including prevention of recurrence and metastasis. However, osteosarcoma responds poorly to current standard immunotherapies due to A) inactivation of the immune system, B) resistance to immunotherapy, and C) difficulty in locally delivering drugs to tumour sites. Immunotherapies can achieve long-term effects including prevention of metastasis and recurrence. There remains huge room for improvement for immunotherapy in osteosarcoma as many patients suffer due to lack of treatment options and recurrence/metastasis.  

Read more

BACKGROUND TO THE RESEARCH PROJECT

The project focuses on understanding and preventing the growth of cancer cells in osteosarcoma patients, as well as looking to stop the spread of cancer around the body. The ability of osteosarcoma to metastasise or spread to different sites is what makes it so aggressive and therefore focusing the research on this is really important. Michael is looking at repurposing a pre-existing drug, which is currently used to treat neonatal jaundice, to block the action of HO-1. HO-1 is a factor which is produced by osteosarcoma patients and prevents the activation of the immune system. By 'kick-starting' the immune system into action, the project will assess if the chemotherapy drugs are able to fight the cancer and stop it from moving to other areas of the body.

Read more